Narayan K, McKenzie A F, Hicks R J, Fisher R, Bernshaw D, Bau S
Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia.
Int J Gynecol Cancer. 2003 Sep-Oct;13(5):657-63. doi: 10.1046/j.1525-1438.2003.13026.x.
The aims of this study were to determine, firstly, the relationship between FIGO stage and various tumor parameters determined by magnetic resonance imaging (MRI), and, secondly, whether any of these parameters were predictors of lymph node metastases as determined by fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) in cervical cancer patients referred for radiotherapy. In 70 consecutive patients, both PET and MRI visualized all primary tumors except for one previously removed by cone biopsy. While clinical diameter and MRI-derived diameter showed a significant relationship between these two measurements (r = 0.70; P < 0.001) there was a large variability in MRI diameter for each FIGO stage and wide overlap. The average volume of primary cervical tumor on MRI was 60 cc (5-256). In FIGO stages, I, II, III and IV, uterine body involvement was present in 58%, 73%, 88%, and 100% of 19, 30, 16, and 5 patients, respectively (Ptrend= 0.015). Node positivity on FDG PET was present in 11% of patients without uterine body extension, but increased to 75% in those with uterine involvement. Average tumor volume in node-negative patients was 49 cc (5-186). Average tumor volume in node-positive patients was 69 cc (8-256). There was a significant association between nodal involvement and both FIGO stage (P = 0.018) and uterine body involvement (P < 0.001), but tumor volume and longitudinal MRI diameter were not statistically significant in unifactor predictors of nodal involvement. In multivariate analysis only uterine body extension, however, was independently related to the risk of nodal involvement. In conclusion, MRI provides noninvasive tumor size evaluation and can also demonstrate invasion of the uterine body that appears to be associated with an increased risk of nodal metastasis. This may provide clinically important prognostic information not available from current FIGO staging.
本研究的目的,其一,是确定国际妇产科联盟(FIGO)分期与通过磁共振成像(MRI)测定的各种肿瘤参数之间的关系;其二,是确定在转诊接受放疗的宫颈癌患者中,这些参数是否为通过氟-18氟脱氧葡萄糖正电子发射断层扫描(FDG PET)测定的淋巴结转移的预测指标。在70例连续患者中,PET和MRI均显示出所有原发性肿瘤,只有1例之前已通过锥形活检切除。虽然临床直径和MRI得出的直径在这两种测量之间显示出显著关系(r = 0.70;P < 0.001),但每个FIGO分期的MRI直径存在很大变异性且重叠广泛。MRI上原发性宫颈肿瘤的平均体积为60立方厘米(5 - 256)。在FIGO分期为I、II、III和IV期的患者中,19例、30例、16例和5例患者的子宫体受累情况分别为58%、73%、88%和100%(P趋势 = 0.015)。FDG PET显示淋巴结阳性在无子宫体延伸的患者中占11%,但在有子宫受累的患者中增至75%。淋巴结阴性患者的平均肿瘤体积为49立方厘米(5 - 186)。淋巴结阳性患者的平均肿瘤体积为69立方厘米(8 - 256)。淋巴结受累与FIGO分期(P = 0.018)和子宫体受累(P < 0.001)均存在显著关联,但肿瘤体积和MRI纵向直径在淋巴结受累的单因素预测指标中无统计学意义。在多因素分析中,然而,只有子宫体延伸与淋巴结受累风险独立相关。总之,MRI可提供无创性肿瘤大小评估,还能显示子宫体侵犯,这似乎与淋巴结转移风险增加相关。这可能提供目前FIGO分期无法获得的重要临床预后信息。